XOMA Corporation (NASDAQ:XOMA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
A number of other equities analysts also recently commented on XOMA. HC Wainwright assumed coverage on XOMA Corporation in a research report on Monday, June 12th. They set a “buy” rating and a $15.00 price objective for the company. ValuEngine raised XOMA Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. Finally, Wedbush reissued a “hold” rating on shares of XOMA Corporation in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $14.00.
Shares of XOMA Corporation (NASDAQ XOMA) opened at 20.15 on Tuesday. The company’s market capitalization is $153.10 million. The stock has a 50 day moving average of $11.46 and a 200-day moving average of $7.86. XOMA Corporation has a 12-month low of $3.96 and a 12-month high of $20.49.
An institutional investor recently raised its position in XOMA Corporation stock. California Public Employees Retirement System lifted its stake in shares of XOMA Corporation (NASDAQ:XOMA) by 95.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,780 shares of the biotechnology company’s stock after buying an additional 10,640 shares during the quarter. California Public Employees Retirement System owned approximately 0.29% of XOMA Corporation worth $123,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 32.92% of the company’s stock.
XOMA Corporation Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.